STOCK TITAN

Nanobiotix S.A. American Depositary Shares - $NBTX STOCK NEWS

Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: $NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nanobiotix S.A. American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nanobiotix S.A. American Depositary Shares's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
Nanobiotix S.A. American Depositary Shares

Nasdaq:NBTX

NBTX Rankings

NBTX Stock Data

343.44M
20.76M
19.68%
0.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Paris

About NBTX

nanobiotix (euronext: nano / isin: fr0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. the company’s first-in-class, proprietary technology, nanoxray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients. nanoxray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. nbtxr3 is being evaluated in: soft tissue sarcoma (sts), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). additionally, head and neck cancer and rectal cancer trials led by nanobiotix’s taiwanese partner, pharmaengine, are underway in the asia pacific region. the company started a new preclinical research program in immuno-oncology with its lea